Current anticancer therapy is a delicate balance between elimination of malignant cells and harmful side effects for the host. In this study, we used a tumor-homing peptide to engineer anti-CD40 agonist antibodies and recombinant IL-2 such that they were selectively delivered into spontaneously arising tumors in a transgenic mouse model of islet cell carcinogenesis. Intravenous injection of these agents, either separately or together, led to accumulation in the vicinity of tumor neovessels without toxic side effects. Although both molecules are critical for adaptive immunity, the most profound effects were seen in endothelial cells. Combined, local anti-CD40 and IL-2 therapy reduced tumor vascularity and significantly delayed tumor growth in mice. Remarkably, tumor-bearing mice remained disease-free long-term when targeted anti-CD40 and IL-2 were combined with transfers of preactivated antitumor immune cells. In this therapeutic setting, triggering of CD40 on endothelial cells induced an inflammatory response of the vessel wall and facilitated effector cell accumulation in the tumor parenchyma while IL-2 promoted antigen-specific immune cell persistence. We believe this is a novel and highly effective anticancer approach, whereby tumor stroma is "conditioned" for enhanced immune cell entry and survival, facilitating immune-mediated tumor destruction and leading to a sustained antitumor response.
Introduction
Much effort has been directed to develop reagents that target tumor- or stroma-specific antigens as a means of delivering bioactive molecules into deeply embedded tumors (1, 2) . Selectively targeting tumor vascular endothelium is of particular interest since it is strikingly different to normal tissue vasculature (3). Joyce et al. have recently used in vivo phage display screening to identify peptides that specifically bind to tumor vasculature but not to normal pancreatic vessels in a transgenic mouse model of islet carcinogenesis (4) . In these RIP-Tag mice, SV40 large T antigen (Tag) expression is controlled by the rat insulin gene promoter (RIP), which leads to stepwise formation of insulinomas through a well defined pathway (5) . Here we use such a tumor-homing peptide (RGR peptide, CRGRRST) to specifically deliver potent immune stimulatory agents, agonistic CD40 antibody and IL-2, into inaccessible, spontaneously developing RIP-Tag tumors. Adjuvant CD40 antibody therapy has been reported to enhance antitumor immunization strategies (6) (7) (8) or promote tumor elimination as a single agent (9) (10) (11) in mouse models. These beneficial antitumor effects were mainly attributed to a crucial role of CD40 in the maturation of dendritic cells (DCs) and to substitute for CD4 + help in priming cytotoxic T lymphocyte (CTL) responses (12) (13) (14) . More recently, it has been reported that combining CD40-mediated CTL activation with immune-reactive cytokines such as IL-2 (15) results in greater antitumor responses than using single agents (16) . Although clinically approved, systemic IL-2 in humans is associated with significant toxicity, limiting its application (17) . Similarly, low-dose systemic anti-CD40 monoclonal antibodies have also been associated with toxic inflammatory syndromes in mice (11) and now humans (18) .
In the present study, we aimed to provide proof of principle that tumors that are deeply embedded in the parenchyma, as many human cancers are, can be targeted via the blood circulation with reduced systemic toxicity. Moreover, we analyzed the impact of locally enriched anti-CD40/IL-2 treatment on progressive tumor growth and antitumor immunity. Finally, we translated our findings into a highly efficient combination therapy, which "preconditions" the tumor by targeting the stroma, thus enabling specific effector T cells to access and destroy the tumor.
Results

Peptide-mediated homing of immune stimulatory agents into solid tumors.
RIP1-Tag5 transgenic mice develop angiogenic islets, some of which become vascularized tumors (insulinomas) by the age of 30 weeks (19, 20) . RGR peptide (CRGRRST) homes into the aberrant vasculature of these angiogenic islets and tumors (4) . We exploited these properties to focally deliver anti-CD40 antibodies and IL-2 directly into the tumors. RGR peptide was conjugated to anti-CD40 antibodies (FGK45) with a myc epitope linker (anti-CD40-RGR). Successful coupling was demonstrated in a western blot using anti-myc antibodies ( Figure 1A ). In addition, a recombinant fusion protein of murine IL-2 and C-terminal RGR peptide (IL-2-RGR) was bacterially expressed and shown to be as bioactive as recombinant unconjugated human or murine IL-2 in stimulating IL-2-dependent T cell proliferation ( Figure 1B ). To test their intratumoral homing capacity, both RGR-coupled agents were injected i.v. into 27-week-old, tumor-bearing RIP1-Tag5 mice and allowed to circulate for 5 minutes. Specific targeting of the compounds to the vicinity of tumor blood vessels was shown by immunohistochemistry ( Figure 1, C and D) . Liver, kidney, lung, or normal pancreatic tissue did not display immune reactivity (data not shown). This is consistent with studies by Joyce et al., which first demonstrated the exclusive binding capability of RGR-FITC molecules to angiogenic vessels in RIP-Tag tumors (4) . Moreover, compared with unconjugated compounds, anti-CD40-RGR/IL-2-RGR treatment induced limited liver toxicity, as assessed by serum alanine aminotransferase and serum TNF-α ( Figure 1 , E and F) (21) and reduced systemic immune responses ( Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI33201DS1). Our data thus demonstrate that vascular targeting is a viable approach to deliver immune-modulating, and otherwise systemically toxic, agents into tumors, which are not accessible by direct intratumoral injections.
Combined intratumoral anti-CD40/IL-2 therapy reduces tumor vascularity. To assess the efficacy of intratumoral anti-CD40/IL-2 therapy, tumor-bearing 23-week-old RIP1-Tag5 mice (average tumor burden at 23 weeks, 53 ± 43 mm 3 ) were treated with anti-CD40-RGR and/ or IL-2-RGR over 10 weeks and survival was monitored (Figure 2A ). Untreated RIP1-Tag5 mice succumb to insulinomas at the age of 28 ± 3 weeks due to overproduction of insulin and hypoglycaemia ( Figure 2B ; end-stage tumor burden at 28 ± 3 weeks, 120 ± 52 mm 3 ; "end-stage" is defined as decrease in blood glucose levels below 30 mg/100 ml indicative of imminent death). Of note, long-term i.v. treatment with anti-CD40 antibodies (FGK45, unconjugated) combined with IL-2 (without RGR peptide) had some beneficial effects in 20% of treated mice. However, 40%-50% of treated mice died unexpectedly after 2-3 weeks of treatment indicative of systemic toxicity ( Figure 2B ). Tumor targeted IL-2-RGR treatment alone had no effect on the overall survival of transgenic mice ( Figure 2C ; end-stage tumor burden at 29 ± 2 weeks, 110 ± 46 mm 3 ). Intratumoral anti-CD40-RGR alone conferred a small but statistically significant survival advantage ( Figure 2C ; end-stage tumor burden at 31 ± 2 weeks, 120 ± 38 mm 3 ; P = 0.02). In contrast, a dramatic therapeutic effect was observed with anti-CD40-RGR/IL-2-RGR combination treatment. In this group, no premature death was recorded and 40% of treated mice survived up to 50 weeks before they succumbed to insulinomas ( Figure 2C ; end-stage tumor burden at 50 weeks, 115 ± 60 mm 3 ; P < 0.005).
To investigate the effects which promoted long-term survival in the anti-CD40-RGR/IL-2-RGR group, pancreata from 30-weekold mice (after 7 weeks of therapy) were harvested for histology (n = 5 mice). Size-matched tumors from all treatment groups (50-70 mm 3 ) were compared. In anti-CD40-RGR/IL-2-RGR-treated tumors, CD31 staining revealed significantly reduced vascularity ( Figure 3A , left panel). This is in clear contrast to tumors from anti-CD40/IL-2 combination groups ( Figure 3A , right panel). Tumor vascularity was quantified across all treatment groups and confirmed the significant, low vessel count after intratumoral anti-CD40/IL-2 treatment ( Figure 3A ; P = 0.005). The dramatically reduced blood supply correlated with a strong increase in tumor hypoxia ( Figure 3B ; P = 0.005). Surprisingly, none of the treated tumors had any significant T cell ( Figure 3C , for CD8 + T cells) or B cell (data not shown) infiltrate and quantification of infiltrating CD4 + and CD8 + T cells did not reveal statistically significant differences between untreated RIP1-Tag5 tumors and treatment groups. These findings indicate a direct antivascular effect of combined anti-CD40-RGR/IL-2-RGR treatment but not anti-CD40-RGR or IL-2-RGR alone, which ultimately impairs tumor growth. To further test this hypothesis, anti-CD40-RGR/IL-2-RGR treatment was repeated in 23-week-old RIP1-Tag5 mice, which were depleted of CD4 + and CD8 + T cells for a period of 5 weeks ( Figure 3D ). This treatment had no impact on progressive tumor growth in RIP1-Tag5 mice. Interestingly, control IgG-treated and -depletion groups responded equally well to intratumoral therapy (Figure 3E). The reduced vessel count in these groups ( Figure 3F ) further substantiates our finding that anti-CD40-RGR/IL-2-RGR therapy exerts major effects on the tumor stroma.
Intratumoral anti-CD40 therapy predominantly acts on tumor endothelium. The lack of immune cells in tumors and profound antiangiogenic effects after combined anti-CD40-RGR/IL-2-RGR treatment raises the question of which cell type intratumoral anti-CD40 antibody targets. This is of particular interest since CD40 expression is not restricted to immune cells but also detected on nonhematopoietic stromal cells, like fibroblasts, vascular endothelium, and tumor cells (22) (23) (24) , and thus, may exert pleiotropic effects on immune and tissue resident cells. We assessed CD40 expression in insulinomas of 27-week-old RIP1-Tag5 mice ( Figure  4A ) and, surprisingly, found expression exclusively on a majority of endothelial cells within the tumor bed. CD40 expression has been reported for a panel of normal endothelia in particular in lung and kidney (23, 25) . However, by immunohistochemistry, vessels of normal pancreas had undetectable CD40 expression levels ( Figure 4B ), indicating a specific upregulation of CD40 on tumor vessels. Thus, endothelial cells are likely targets for intratumoral anti-CD40 therapy. This finding prompted us to establish CD40-knockout RIP1-Tag5 bone marrow chimeras (CD40 -/-→RT5) where all bone marrow-derived cells lack the CD40 molecule, but the majority of tumor endothelial cells still express CD40 ( Figure  4C ). In addition, crossing RIP1-Tag5 mice into a CD40-deficient background and providing wild-type (C3H) bone marrow creates chimeric mice (C3H→RT5×CD40 -/-) with CD40-responsive immune cells, but most tumor vessels lack CD40 expression (Figure 4D ). Tumorigenesis in chimeric RIP1-Tag5×CD40 -/-mice was unchanged as compared with wild-type RIP1-Tag5 mice ( Figure  4E ). Upon treatment with anti-CD40-RGR/IL-2-RGR combination therapy, only chimeric mice with CD40 + tumor vessels were responsive and survive long-term ( Figure 4F ; P = 0.004). In contrast, treated C3H→RT5×CD40 -/-mice only had a small survival advantage over untreated C3H→RT5×CD40 -/-mice ( Figure 3E ; P = 0.03, P values compared to corresponding controls in Figure  4E ). These data demonstrate a critical role of tumor endothelia as direct targets for intratumoral anti-CD40 therapy. (26), and anti-CD40-RGR/IL-2-RGR combination therapy elicited a transient increase in immune cell infiltration during the first 2 weeks of treatment (data not shown). However, this spontaneous infiltration was resolved by week 30. Thus, we hypothesized that by providing ex vivo activated antitumor effector cells therapeutic efficacy might be substantially improved. Tumor-bearing RIP1-Tag5 mice were treated as indicate in Figure 2A , with adoptive transfers of antiTag CD4 + and CD8 + T cells (from TCR mice; refs. 27, 28) every 3 weeks. Regular adoptive transfers of activated CD4 + and CD8 + T cells did not significantly prolong survival in tumor-bearing RIP1-Tag5 mice (29 ± 3 weeks) (19) , which was also comparable to treatment with IL-2-RGR and adoptive transfers (31 ± 2 weeks). Intratumoral anti-CD40-RGR and adoptive transfers produced a better survival outcome (37 ± 4 weeks; P = 0.0001). Importantly, 80% of mice treated with the triple combination of intratumoral anti-CD40-RGR/IL-2-RGR and adoptive transfers survived long-term ( Figure 5A ; P < 0.0001). Upon termination at week 45, all surviving mice had normal pancreata without macroscopic tumor nodules. Interestingly, the tumor-selective destruction did not lead to a total loss of β cells and consequent diabetes, possibly due to selective downregulation of Tag expression (Supplemental Figure 2) . Eight long-term survivors of the triple treatment were monitored beyond week 45 and survived for more than 90 weeks. New tumors arose after a lengthy period without treatment due to continuos oncogene expression in pancreatic β cells.
Combined intratumoral targeting of anti-CD40 antibodies and IL-2 dramatically improves adoptive immunotherapy. RIP1-Tag5 mice are not tolerant toward the model tumor antigen Tag
Furthermore, tumor specificity is required for immune-mediated destruction since concanavalin A-activated (ConA-activated), unspecific T cells did not enhance the previously observed survival benefits of combined anti-CD40-RGR/IL-2-RGR therapy ( Figure  5B) . Surprisingly, therapeutic success of the triple treatment (anti-CD40-RGR/IL-2-RGR, adoptive transfers) was mirrored in RIP1-Tag5 mice reconstituted with bone marrow from CD40 -/-mice but failed in C3H→RT5×CD40 -/-chimeric mice ( Figure 5C ). Again, this finding implies an important role of CD40-expressing tumor vessels in mediating the beneficial effects of the triple therapy. We therefore monitored changes in the vascular compartment after 3 consecutive anti-CD40-RGR injections at the time when the first activated anti-Tag effector cells were injected (age 26 weeks). Remarkably, tumor-targeted anti-CD40 therapy dramatically upregulated endothelial expression of ICAM, VCAM, and E-selectin ( Figure 5D ). This upregulation is not observed in IgG- or RGR peptide-treated control insulinomas ( Figure 5D ) or in exocrine pancreatic tissue, liver, lung, and kidney (data not shown).
Intratumoral anti-CD40/IL-2 enhances immune effector cell accumulation in tumors. Activation of tumor endothelia after anti-CD40
treatment may enhance effector cell entry into the tumor. To test this, tumors from different treatment groups were harvested 7 days after the first adoptive transfers (Figure 2A ; age 27 weeks) and analyzed by histology. Remarkably, an increased T cell infiltration was documented when preactivated, Tag-specific T cells were adoptively transferred into anti-CD40-RGR-treated RIP1-Tag5 mice. An even more dramatic accumulation of anti-Tag T cells into tumors was observed when anti-CD40-RGR was combined with IL-2-RGR, followed by adoptive transfer. In contrast, IL-2-RGR preconditioning alone had no effect on endothelial activation (data not shown) or lymphocytes in the tumor (Figure 6A) . Nevertheless, IL-2 is highly beneficial during therapy. To further analyze the role of intratumoral IL-2, anti-Tag CD8 + T cell survival was monitored by their isolation from lymph nodes and tumors at different time points after transfer ( Figure 6B ). Preactivated anti-Tag T cells specifically homed into tumor-draining pancreatic lymph nodes where they proliferated, reaching a peak at day 7 after transfer; without further manipulation, these activated T cells do not accumulate in the tumor (29) . Intratumoral IL-2 only extended the survival of T cells in lymph nodes. In contrast, anti-CD40-RGR antibody enhanced extravasation of adoptively transferred T cells, which transiently accumulated in the tumor, although the majority of T cells remained in the pancreatic lymph nodes; their survival was not extended in either site. Only when anti-CD40-RGR was combined with IL-2-RGR did the majority of adoptively transferred T cells locate into the tumor, and their survival was prolonged up to 28 days. These data imply a critical role for intratumoral anti-CD40 in T cell penetration, most likely through activation of angiogenic vessels. Once effector cells accumulate in the tumor, IL-2 promotes T cell persistence. Thus, anti-CD40 and IL-2 combination therapy acts in concert to substantially enhance intratumoral infiltration by adoptively transferred effector cells, which in turn leads to destruction of established tumors.
Discussion
In the present work, we have engineered clinically approved, currently used drugs for highly specific, targeted intratumoral delivery. Accumulation of anti-CD40 and IL-2 within the tumor environment had surprising effects on the newly formed vasculature and showed synergistic antitumor efficacy. Moreover, intratumoral anti-CD40/IL-2 therapy potentiated immune effector cell accumulation and persistence in the tumor, resulting in a dramatically improved immunotherapeutic outcome against a highly inaccessible, autochthonous murine tumor.
Intratumoral targeting for anticancer therapy. Our previous studies in RIP1-Tag5 mice have clearly demonstrated that even in the presence of a potent tumor antigen (Tag), immunotherapy fails because effector cell penetration and/or function within tumors are limited (19, 29, 30) . These limitations are reflected in the general lack of success when applied to cancer patients, even though generation of tumor-specific CTLs is often reported (31) . However, manipulating the tumor to enhance permissiveness while avoiding toxicities of systemically delivered immune-stimulating reagents remains a major challenge. The logical alternative approach is to target these agents directly into the tumor bed. A unique and highly specific way to deliver therapies into inaccessible, autochthonous tumors in mice and humans is to exploit the abnormal features of the tumor environment itself. Although this approach is in its infancy, there is accumulating evidence that each tumor bed has a specific "address" that can be targeted (4, 32, 33) . Here, we used the RGR peptide, which specifically homes to neoplastic vessels in the pancreas of RIPTag mice. The RGR peptide has homology to PDGF-B and is a putative ligand for PDFGRβ. In RIP-Tag tumors, RGR colocalizes with endothelial cells and pericytes, a supportive vascular cell type surrounding endothelial cells (4). This peptide was used as a vehicle to target agonistic CD40 antibodies and/or recombinant IL-2 into highly angiogenic, aggressively growing islet cell carcinomas. These 2 agents were selected because of their documented immune-enhancing and potential vascular effects (15, 34) , both essential criteria for therapeutic efficacy in RIP1-Tag5 mice (31) .
Antitumor effects of agonistic CD40 antibodies have been extensively studied in a variety of mouse models with a major focus on their immune-enhancing properties (6-9, 11). Although CD40 agonist antibodies are in current clinical trials, recent publications raise concerns that systemic stimulation of CD40 may have pleiotropic and undesired effects. For instance, the induction of cytokine release syndrome (11, 18) may relate to a CD40-induced inflammatory reaction in the vessel wall of normal organs (34) . Furthermore, although systemic CD40 antibody in combination with IL-2 therapy has been reported to generate a strong initial antitumor immune response, the same regimen impairs memory response, leading to an inability to maintain a durable antitumor immunity (35) . These recently documented, profound adverse effects of systemic anti-CD40/IL-2 treatment, together with our own findings in RIP1-Tag5 mice ( Figure 2B ), strongly support the need for targeted delivery into the tumor microenvironment.
Effectiveness of targeted anti-CD40/IL-2 therapy. We report here that sustained local anti-CD40/IL-2 therapy exerts major effects on tumor blood vessels. We believe this is a novel finding that demonstrates that local therapy is distinctively different to systemic drug delivery. To date, the beneficial effects of systemic anti-CD40/IL-2 administration have been entirely attributed to their immune-enhancing properties, in particular, activation of DCs by anti-CD40 and improved proliferation of CD8 + T cells by IL-2 (16, 36) . Local enrichment of anti-CD40 and IL-2 in the tumor over at least 5 weeks led to a drastic reduction in tumor vessels, increase in hypoxia, and delay in tumor growth. Strikingly, this effect was only observed in combination therapy. While we have strong evidence that anti-CD40 acts through CD40 expressed on tumor vessels, the role of IL-2 is less well defined. There is evidence that IL-2 causes vascular leak syndrome through direct binding and damaging of endothelial cells (37) . Alternatively, intratumoral IL-2 has been shown to decrease tumor vascularity via activated CD8 + effector cells, which may secret IFN-γ, a molecule with demonstrated antivascular effects (15, 38, 39) . However, the absence of a marked T cell infiltrate in end-stage tumors and our T cell depletion studies argue for direct toxic effects of IL-2 on tumor vessels in anti-CD40-treated RIP1-Tag5 mice.
In light of the controversy of pro- or antiangiogenic effects of anti-CD40 (40) , it is important to note that although anti-CD40 monotherapy had little impact on the overall survival of tumor-bearing RIP1-Tag5 mice, our findings do not support a proangiogenic role of CD40. This is of particular interest since a recent report has implicated CD40-CD40L interactions in the promotion of angiogenesis during mammary carcinogenesis in a transgenic BALB/NeuT tumor model (25) . In the absence of CD40 or by depleting platelets as the source of stimulating CD40L, BALB/NeuT tumors develop slower and lack large vessels. In that analysis, tumors are deprived of CD40 stimulation early during carcinogenesis. In contrast, anti-CD40 therapy as conducted here acts on a well-established, highly angiogenic vasculature in latestage tumors. This suggests that CD40-CD40L interactions have a different impact on tumor angiogenesis depending on the phase of tumor development and possibly signal strength and use of combination drugs.
Tumor targeted anti-CD40/IL-2 and adoptive immunotherapy: new insights. While intratumoral anti-CD40/IL-2 has considerable
impact on the life expectancy of transgenic mice, it merely delays tumor growth. Chronic treatment over at least 5 weeks causes vessel death but fails to activate an effective antitumor immune response. When intratumoral anti-CD40/IL-2 is combined with adoptive transfers of activated antitumor effector cells, CD40 + tumor endothelia again play an important role, but most likely by increasing the potential of effector cells to reach the tumor site. We show here that intratumoral CD40 stimulation activates blood vessels at the time of T cell transfer, which in turn may trigger an inflammatory reaction of the vessel wall (34, 41, 42) and enable accumulation of preactivated, tumor-specific immune cells in the otherwise inaccessible tumor environment. Indeed, local anti-CD40 monotherapy plus adoptive transfers has some beneficial effects on overall survival. This is consistent with a recent report showing that anti-CD40 treatment enhances tumor infiltration by adoptively transferred anti-Tag TCR CD8 + T cells in a C57BL/6 insulinoma model (43) . However effector cells are rapidly cleared, thus limiting therapeutic success. Importantly, we demonstrate here that IL-2 is required to promote persistence of immune effector cells within tumor parenchyma. This accumulation and survival of immune cells is critical for the elimination of cancer cells.
Our findings strongly support a new and highly effective, synergistic, angio-immunotherapeutic approach, where local effects of anti-CD40 antibody plus IL-2 "condition" the tumor environment and are further enhanced when combined with adoptive cell transfers.
Methods
Mice. RIP1-Tag5 transgenic mice (kindly provided by D. Hanahan, UCSF,
San Francisco, California, USA) were used on a C3HebFe background. RIP1-Tag5 are not tolerant towards Tag due to late onset of transgene expression in adult mice. RIP1-Tag5 mice express Tag at around week 8-10, hyperplastic islets arise at around week 14-16, first abnormal vessels develop in angiogenic islets around week 16, and solid tumors form from week 22 on, followed by premature death at week 30 (29) . For adoptive transfer experiments, mice transgenic for a TCR that recognizes Tag presented by the MHC class I molecule H-2K k (referred to as TagTCR8; kindly provided by T. Geiger, St. Jude Children's Research Hospital, Memphis, Tennessee, USA and R. Flavell, Yale University, New Haven, Connecticut, USA) (27) or the MHC class II molecule I-A (TagTCR1; kindly provided by I. Foerster, University of Düsseldorf, Düsseldorf, Germany) (28) were used on a C3H background. For bone marrow chimeras, CD40 -/-mice (44) were backcrossed on a C3H background for at least 5 generations. Lethally irradiated 6-week-old RIP1-Tag5 mice were reconstituted with bone marrow from CD40 -/-mice, or 6-week-old RIP1-Tag5×CD40 -/-mice (prior to onset of tumor formation) were reconstituted with bone marrow from CD40 +/+ (C3H) mice. Absence/ presence of CD40 on spleen cells of CD40 -/-chimeras was confirmed 8 weeks after bone marrow reconstitution (data not shown). All mice were kept under specific pathogen-free conditions at the German Cancer Research Center or the University of Western Australia. All experimental protocols were approved by the Animal Welfare Board of the Regierungspräsidium (Karlsruhe, Germany) or the Animal Ethics Committee of the University of Western Australia, Perth, Western Australia, Australia).
Production of RGR-conjugated anti-CD40 antibodies and western blot analysis. Rat monoclonal antibody FGK45 (anti-mouse CD40; isotype IgG1 kappa, ref. 45 ; a generous gift from K. Melief, University of Leiden, Leiden, The Netherlands) was produced in a miniPERM bioreactor and purified over a goat anti-rat IgG Sepharose CL-4B column. Purified immunoglobulin was dialyzed against PBS and adjusted to a protein concentration of 2 mg/ml. The following peptides (synthesized by Peptide Speciality Laboratories) were conjugated to purified monoclonal anti-CD40 antibodies: RGR, CGGGGGRGRRST-NH2; and myc-RGR, CGGGEQKLISEEDLGGGRGRRST-NH2. For conjugation, the instructions of the Controlled Protein-Protein Cross-linking Kit (Pierce) were followed with minor modifications. temperature, nonreacted cross-linker was removed by dialysis against PBS. Equal molar amounts of maleimide-activated antibody were mixed with sulfhydryl-containing peptide RGR for 60 minutes at room temperature. Nonbound peptide was removed by dialysis against PBS. Two micrograms of anti-CD40 or anti-CD40-RGR antibodies were separated by 7.5% nonreducing SDS/PAGE, and the membrane was probed with 0.5 μg/ml biotinylated anti-myc antibodies (Myc1-9E10; ref. 46 ) and 10 ng/ml streptavidin-HRP (Vector/Alexis Biochemicals). The same membrane was reprobed with 10 ng/ml horse anti-rat IgG-HRP (Vector).
Production of recombinant murine IL-2-RGR fusion protein and assessment of bioactivity. Mature murine IL-2 or IL-2 with a C-terminal modified RGR peptide (CRGRRSTG) were PCR amplified using the following primers (5′-3′): SmaI-IL-2 (GCCCCGGGCGCACCCACTTCAAGCTCCACT) and XhoI-IL-2 (GCCTCGAGGAGGTACATAGTTATTGAGGG) or SmaI-IL-2 and XhoI-IL-2-RGR (GCCTCGAGTCAACCAGTAGAACGACGAC-CACGACAACCACCACCTTGAGGGCTTGTTGAGATGATG), respectively. Amplified products were cloned into Sma1-XhoI sides of pGEX-6P (Amersham Pharmacia) to produce glutathione-S-transferase (GST) fusion products in bacteria as described (47) . Briefly, after isopropyl-β-d-glactopyranoside (IPTG) induction for 2 hours at 37°C, cultures were centrifuged, resuspended in ice-cold PBS, sonicated, and protein was resolved in 8 M urea solution containing 50 mM Tris-HCl (pH 8.0), 1 mM DTT, and 1 mM EDTA for 1 hour at room temperature. Denatured IL-2 was refolded through a series of dialyses: first, at 4°C against 4 M urea solution (twice, 1 hour each time); next, 2 M urea solution (twice, 1 hour each time); and then, 50 mM Tris-HCl (pH 8.0), 1 mM DTT, 1 mM EDTA (twice, 1 hour each time and once overnight). Solubilized GST-IL-2/IL-2-RGR proteins were purified using a GSTrap FF column according to the manufacture's instructions (Pharmacia), and the GST tags were removed by PreScission protease cleavage (Pharmacia). Recombinant IL-2 was purchased from R&D Systems. IL-2-dependent cytotoxic CTL.L2 T cells were resuspended in RPMI1640 medium, supplemented with 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, 0.05 mM 2-mercaptoethanol, and 5% fetal calf serum. On round bottom microtiter plates, 4 × 10 3 cells in 0.1 ml were seeded. Each well received 0.1 ml of serially diluted recombinant protein, and triplicate cultures were incubated. After 48 hours, 1 μCi of [ 3 H]thymidine (Amersham) was added per well. Cultures were harvested 18 hours later on filter pads with a cell harvester (Titertek; Flow Laboratories), and radioactivity was measured in scintillation fluid.
In vivo treatment of tumor-bearing RIP1-Tag5 mice with fusion compounds. Mice at 23 weeks of age were injected i.v. with 100 μg of anti-CD40-RGR weekly and/or 25 μg IL-2-RGR 3 times per week for a 10-week treatment schedule (Figure 2A) . In some experiments, adoptive transfers were given in 3 weekly intervals in addition to anti-CD40-RGR/IL-2-RGR treatment. In vitro proliferation and adoptive transfers are described elsewhere (19) . Briefly, TagTCR8 splenocytes or TagTCR1 lymph node cells were activated in vitro for 3 days, with 10 U of rIL-2/ml and 25 mM Tag peptide 362-568 (SEFLIEKRI for TagTCR8 cells) or 25 nM Tag peptide 362-384 (TNRF-NDLLDRMDIMFGSTGSADI for TagTCR1 cells). C3H-derived splenocytes were activated with 1 μg/ml ConA (Sigma-Aldrich), and 2.5 × 10 6 activated CD4 + and 2.5 × 10 6 CD8 + T cells were transferred. For T cell depletion studies, anti-L3T4 (anti CD4 + , rat anti-mouse GK1.5 hybridoma) and anti-Lyt.2 (anti-CD8 + , rat anti-mouse 53-6.7) antibodies were produced in a miniPERM bioreactor and column purified. Specific antibodies or purified irrelevant rat IgG (0.5 mg) were injected i.p. for 3 consecutive days prior to anti-CD40-RGR/IL-2-RGR treatment ( Figure 3D ), followed by weekly injections of 1 mg antibodies on day 1, 8, 15, 22, and 29. T cell depletion was monitored by FACS on day 1, 14, and 21 (data not shown).
Assessment of toxicity. Serum alanine aminotransferase activity was determined using bioreaction strips on a Reflovet Plus reader (Roche Diagnostics). Serum TNF-α concentrations were assayed using an Enzyme-Linked Immunosorbent Assay kit according to the manufacturer's protocol (Bio-Scientific).
Histological analyses. For fluorescence detection, recombinant IL-2 proteins were chemically biotinylated with sulfosuccinimidyl-6-(biotinamido)hexanoate (EZ-Link sulfo-NHS-LC-Biotin; Pierce) in 0.150 M NaCl and 0.1 M phosphate buffer, pH 7.2, following the manufacturer's instructions. Free sulfo-NHS-LC-Biotin was removed by dialysis. Mice were injected i.v. with 100 μg anti-CD40-mycRGR or biotinylated IL-2-RGR. After 5 minutes of circulation, mice were sacrificed and organs embedded in OCT compound (Tissue Tek) or, alternatively, hearts of mice were perfused with 4% paraformaldehyde in PBS and embedded in OCT, and 10 μm sections were stained with anti-myc antibodies and the Mouse on Mouse (M.O.M.; Vector) kit detection. Biotinylated IL-2 was detected using streptavidin-FITC (Alexis). Immuohistochemistry was performed as described (29) . For lectin perfusion, mice were i.v. injected with 100 μg of FITC-labeled tomato lectin (Lycopersion esculentum; Vector). After 3 minutes of circulation, hearts of mice were perfused with 4% paraformaldehyde in PBS. Organs were postfixed for 2 hours in PFA, 2 hours in 30% sucrose, and overnight in 10% sucrose and embedded in OTC. For immunohistochemistry the following antibodies were used: anti-ICAM (YN1/1.7.4, 10 μg/ml; ATCC), anti-VCAM (42, 10 μg/ml; BD Pharmingen), E-selectin (UZ4, 10 μg/ml; BD Pharmingen), anti-CD4 (GK1.5, 10 μg/ml; BD Pharmingen), anti-CD8 (Ly-2, 10 μg/ml; BD Pharmingen), anti-CD45 (30-F11, 10 μg/ml; BD Pharmingen), anti-CD40 (rabbit polyclonal, C-20, 20 μg/ml; Santa Cruz Biotechnology Inc.), anti-CD31 (Mec 13.3, 10 μg/ml; BD Pharmingen), and anti-Tag (rabbit polyclonal, 1:1000; a generous gift from D. Hanahan). For secondary detection, the following antibodies were used at 3 μg/ml: anti-rat biotin or anti-rabbit biotin followed by ABC elite kit (Vector), cyanin-3-FITC conjugated IgG F(ab′)2 fragment goat anti-rat (Dianova), and cyanin-3-conjugated donkey anti-goat IgG (Dianova). The hypoxyprobe-1 kit (Chemicon) was used to detect hypoxia. Hypoxic tumor area was quantified throughout tumors on sections that were 100 μm apart. Tumor sections were evaluated for CD8 + lymphocytic infiltration or CD31 + vessels by using a 20× objective lens, and 5 independent areas were selected, digitally photographed, and counted (ImagePro).
Flow cytometry. Lymph node or tumor cell suspensions were stained with biotinylated anti-mouse Vβ 8.1 and 8.2 (2 μg/ml, clone MR5.2; BD Pharmingen), followed by streptavidin-Red670 (1.7 μg/ml; Life Technologies) and phycoerytrin-conjugated anti-CD8 (2 μg/ml, Ly-2; BD Pharmingen) for 2-color analysis. Spleen cells were stained with antibodies against MHC class II (H-2K k , 11.4.1, 5 μg/ml) and CD11c (2 μg/ml, HL3; BD Pharmingen). Cells were analyzed on a FACSCalibur (Becton Dickinson).
Statistics. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. Student's t test (2-tailed) was used unless indicated otherwise. A P value of less than 0.05 was considered statistically significant. Error bars indicate SD.
